Open AccessFeatures of nervous system damage in antiphospholipid syndrome
Author(s) -
О. N. Voskresenskaya,
V. O. Bitsadze,
J. Kh. Khizroeva,
T. A. Sukontseva,
M. V. Tretyakova,
А. С. Шкода,
JeanChristophe Gris,
I. Elalamy,
Giuseppe Rizzo,
Д. В. Блинов,
Alexander Makatsariya
Publication year - 2021
Publication title -
akušerstvo, ginekologiâ i reprodukciâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 4
eISSN - 2500-3194
pISSN - 2313-7347
DOI - 10.17749/2313-7347/ob.gyn.rep.2021.242
Subject(s) - medicine , antiphospholipid syndrome , multiple sclerosis , central nervous system , chorea , immunology , nervous system , migraine , peripheral nervous system , thrombosis , epilepsy , ischemia , pathogenesis , transverse myelitis , neuroscience , pathology , cardiology , antibody , disease , psychiatry , biology
Antiphospholipid syndrome (APS) is an autoimmune process that increases the risk of arterial and venous thrombosis. The mechanism of damage to the central nervous system (CNS) can be not only due to thrombosis, but also antiphospholipid antibodies (APA) circulating in the peripheral blood. The latter can damage the cerebral vascular endothelium, alter the resistance of the blood-brain barrier and penetrate into the central nervous system, exerting a damaging effect on astroglia and neurons, as evidenced by the release of neurospecific proteins into the peripheral bloodstream. The role of APS in developing cerebral ischemia, migraine, epilepsy, chorea, transverse myelitis, multiple sclerosis, cognitive impairment and mental disorders, as well as the peripheral nervous system is described. It should also be noted about a role of APS for emerging neurological disorders in COVID-19, enabled apart from thrombogenesis due to APA via 2 potential mechanisms - molecular mimicry and neoepitope formation. Further study of the APS pathogenesis and interdisciplinary interaction are necessary to develop effective methods for patient management.